Log in

VNRX VOLITIONRX LTD NYSE · United States

VOLITIONRX LTD (VNRX) news VNRX offering news

Latest VOLITIONRX LTD news

  1. Debt Financing

    VolitionRx gets Lind waiver for ATM sales above $10 million

    Lind Global Asset Management XII waived defaults tied to at-the-market sales above the $10 million annual cap on notes issued in 2025 and 2026.

VOLITIONRX LTD annual financials

LineFY2025FY2024
Revenue$1.7 million$1.2 million
Research and development$10.1 million$14.4 million
Net income (loss)-$23.4 million-$27.0 million
Cash from operations-$19.7 million-$25.9 million
Cash and equivalents$1.1 million$3.3 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.8 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about VOLITIONRX LTD

Has VOLITIONRX LTD raised money recently?

Our latest story on this, dated Sep 2, 2026: "VolitionRx gets Lind waiver for ATM sales above $10 million". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of VOLITIONRX LTD?

VOLITIONRX LTD trades under the ticker VNRX on NYSE.

Where is VOLITIONRX LTD listed?

VOLITIONRX LTD is listed on NYSE.

Which country or territory is VOLITIONRX LTD listed under?

Our directory records VOLITIONRX LTD under United States.

Does aibio.space cover VOLITIONRX LTD?

aibio.space lists VOLITIONRX LTD among 2,820 public biotech companies and publishes its news here as stories appear.

What was VOLITIONRX LTD's revenue last year?

$1.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is VOLITIONRX LTD profitable?

VOLITIONRX LTD reported a net loss of $23.4 million for the fiscal year ended Dec 31, 2025, and used $19.7 million of cash in operations, per its annual report to the SEC.

How much does VOLITIONRX LTD spend on research and development?

$10.1 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does VOLITIONRX LTD have?

$2.8 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest VOLITIONRX LTD (VNRX) stock news?

Our latest story on VOLITIONRX LTD, dated Oct 27, 2026: "VolitionRx prepays $500,000 on Lind note and defers two monthly payments". The remaining balance is $706,667 after the payment. Lind agreed not to convert before January 1, 2027 unless the stock closes at $0.275 or more. Source.

Does VOLITIONRX LTD have debt, a term loan or convertible notes?

Our latest debt story, dated Oct 27, 2026: "VolitionRx prepays $500,000 on Lind note and defers two monthly payments". The remaining balance is $706,667 after the payment. Lind agreed not to convert before January 1, 2027 unless the stock closes at $0.275 or more. Source.

How can I follow VOLITIONRX LTD (VNRX) news?

Press Follow on this page to add VOLITIONRX LTD to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming VOLITIONRX LTD so far, in Debt Financing.

Investor discussion: VOLITIONRX LTD

Members talk about VOLITIONRX LTD (VNRX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at VOLITIONRX LTD, newest first. Each line links the filing it comes from.

  1. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source

  2. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source

  3. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source

  4. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NYSE:VNRX on TradingView.

Listing details

VOLITIONRX LTD is a public biotech or pharmaceutical company listed on NYSE under the ticker VNRX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
VOLITIONRX LTD
Ticker
VNRX
Listing
NYSE
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.